Shire to buy Baxalta for $32 billion, forging rare diseases leader

LONDON (Reuters) - Drugmaker Shire Plc clinched its six-month pursuit of Baxalta International Inc on Monday by agreeing a $32 billion cash and stock offer that will make it one of the world's leading rare disease specialists.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro